RxDoctor Payments Data

Lucas Mikulic, MD

Pulmonary Disease · Clearwater, FLNPI 1093998742

Payments from drug & device makers

$4,207in general payments, 2019–2025

Across 216 payments — averaging $19.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$601
  • GSK$510
  • Insmed, Inc.$463
  • Boehringer Ingelheim$257
  • Actelion Pharmaceuticals US, Inc.$253
  • Amgen$253
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$4,207100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,207 in reported general payments places this provider in the 50th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$239,026
Medicare patients
584
Services billed
1,918

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate16$207,750
Trelegy ElliptaFluticasone/Umeclidin/Vilanter151$149,126
NucalaMepolizumab14$59,950
Breztri AerosphereBudesonide/Glycopyr/Formoterol49$38,221
Breo ElliptaFluticasone/Vilanterol48$31,068
Stiolto RespimatTiotropium Br/Olodaterol Hcl32$26,434
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr51$23,145
Spiriva RespimatTiotropium Bromide16$17,291
Advair HfaFluticasone Propion/Salmeterol12$9,225
Combivent RespimatIpratropium/Albuterol Sulfate16$7,777
SymbicortBudesonide/Formoterol Fumarate21$7,456
Spiriva HandihalerTiotropium Bromide13$6,732
XareltoRivaroxaban12$6,568
EliquisApixaban11$6,285
Albuterol Sulfate HfaAlbuterol Sulfate113$3,446

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta$510$263,289264 claims
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat$257$259,25280 claims
AstraZenecaBreztri Aerosphere, Symbicort$601$45,67770 claims
Johnson & JohnsonXarelto$43$6,56812 claims
PfizerEliquis$38$6,28511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in Clearwater

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →